AVANIR Pharmaceuticals Invites Investors to Its First Quarter Conference Call on February 9, 2006
18 Gennaio 2006 - 2:30PM
Business Wire
AVANIR Pharmaceuticals (AMEX: AVN.R) will webcast its quarterly
conference call on Wednesday, February 9, 2006 at 1:30 p.m.
Pacific/ 4:30 p.m. Eastern. The call will be webcast live through
AVANIR's corporate website at www.avanir.com and will feature Eric
Brandt, President and Chief Executive Officer, and Gregory P.
Hanson, Vice President and Chief Financial Officer. A press release
announcing the first quarter 2006 financial results will be
released prior to the conference call the same day. It is
recommended that you go to AVANIR's website at least 10 minutes in
advance of the webcast to download any applicable software. For
those who cannot listen to the live broadcast, the online replay
will be available for 90 days, and a phone replay will be available
through February 13, 2006, by dialing 800-642-1687 (domestic) and
706-645-9291 (international) and entering the passcode 4490357.
AVANIR Pharmaceuticals is focused on developing and commercializing
novel therapeutic products for the treatment of chronic diseases.
AVANIR's product candidates address therapeutic markets that
include central nervous system and cardiovascular disorders,
inflammation, and infectious diseases. AVANIR previously announced
positive results in the second of two required Phase III clinical
trials of Neurodex(TM), an investigational new drug for the
treatment of pseudobulbar affect. Additionally, AVANIR has
initiated a Phase III clinical trial for Neurodex as a potential
treatment in patients with diabetic neuropathic pain, a second
indication for Neurodex. AVANIR has active collaborations with two
international pharmaceutical companies: Novartis International
Pharmaceutical Ltd. for the treatment of inflammatory disease and
AstraZeneca for the treatment of cardiovascular disease. The
Company's first commercialized product, Abreva(R), is marketed in
North America by GlaxoSmithKline Consumer Healthcare and is the
leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.
The information contained in this press release, including any
forward-looking statements contained herein, should be reviewed in
conjunction with the company's most recent Annual Report on Form
10-K and quarterly report on Form 10-Q and other publicly available
information regarding the Company. Copies of such information are
available from the company upon request. Such publicly available
information sets forth many risks and uncertainties related to the
company's business and technology. Forward-looking statements often
contain such words like "estimate," "anticipate," "believe," "plan"
or "expect". Avanir disclaims any intent or obligation to update
these forward-looking statements.
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Avanir Pharmaceuticl (Borsa Americana (AMEX)): 0 articoli recenti
Più AVANIR Pharmaceuticals Articoli Notizie